Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
X4 Pharmaceuticals
Biotech
X4 lays off 30% of staff to focus on Xolremdi rollout
X4 is laying off 30% of staff and halting preclinical R&D as it channels resources into recently approved rare disease drug mavorixafor.
James Waldron
Feb 6, 2025 8:12am
Mirati CEO exits—Chutes & Ladders
Aug 11, 2023 9:30am
X4 scores a phase 3 win for immune deficiency disorder drug
Nov 30, 2022 10:45am
Rubius execs depart as the walls close in—Chutes & Ladders
Nov 4, 2022 9:30am
X4 joins handful of biotechs sending staff out the door
Jul 21, 2022 10:55am
Novartis alums unveil their next act—Chutes & Ladders
Nov 6, 2020 9:30am
